Skip to content

Released May 13, 2021, after the close

10-Q filed May 13, 2021, 43 days after period end · 0001390478-21-000017

Q1 2021 · 10-Q
Revenue$5.70M— vs Q1 2020+200.0% vs Q4 2020
Net Income-$2.40MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.16N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$2,245,000N/M
Operating Cash Flow-$10,269,000N/M
Margins · derived
Operating margin-39.4%
Net margin-42.2%

What the release said

The release

Same quarter

MetricQ1 2021Q1 2020Q1 2019Q1 2018
Revenue$5.70M$0.00——
Net Income-$2.40M-$4.14M-$4.54M-$8.00M
EPS Diluted-$0.16-$0.66-$11.12-$1.67

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR